{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:55:23Z","timestamp":1758981323239,"version":"3.44.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1053\/j.seminhematol.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T12:39:20Z","timestamp":1527511160000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in diagnosis of mastocytosis and hypereosinophilic syndrome\u2606"],"prefix":"10.1053","volume":"56","author":[{"given":"Irina","family":"Maric","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2018.05.005_bib0001","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0002","series-title":"World Health Organization (WHO) classification of tumors. Pathology & genetics. Tumors of haematopoietic and lymphoid tissues","article-title":"Mastocytosis","author":"Horny","year":"2016"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajh.24490","article-title":"Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study","volume":"91","author":"Broesby-Olsen","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jaci.2015.04.024","article-title":"Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis","volume":"136","author":"Carter","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0006","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0007","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0008","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase\u2014the stem cell factor receptor","volume":"337","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0011","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2011.293","article-title":"An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis","volume":"26","author":"Teodosio","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0012","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0014","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0017","doi-asserted-by":"crossref","unstructured":"Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 130:804-815.","DOI":"10.1038\/jid.2009.281"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0018","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0019","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0020","first-page":"159","article-title":"Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology","volume":"3","author":"Valent","year":"2013","journal-title":"Am J Cancer Res"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0021","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J Pathol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0022","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0023","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/labinvest.3700524","article-title":"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation","volume":"87","author":"Nakagomi","year":"2007","journal-title":"Lab Invest"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0024","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1200\/JCO.2012.41.9549","article-title":"Mast cell sarcoma: a rare and aggressive entity\u2013report of two cases and review of the literature","volume":"31","author":"Georgin-Lavialle","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0025","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0026","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0027","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0028","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0029","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Hanssens","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccr.2011.06.025","article-title":"The role of TET2 in hematologic neoplasms","volume":"20","author":"Holmfeldt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0031","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0032","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1101\/cshperspect.a003707","article-title":"Spliceosome structure and function","volume":"3","author":"Will","year":"2011","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0034","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/leu.2012.130","article-title":"Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0035","doi-asserted-by":"crossref","first-page":"17588","DOI":"10.1074\/jbc.M512616200","article-title":"Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor","volume":"281","author":"Cho","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0036","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaci.2012.04.013","article-title":"Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations","volume":"130","author":"Broesby-Olsen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0037","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0038","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0039","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0040","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1038\/bcj.2015.9","article-title":"Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome","volume":"5","author":"Patnaik","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0041","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0042","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0043","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"year":"2008","series-title":"World Health Organization (WHO) classification of tumors of haematopoietic and lymphoid tissues","key":"10.1053\/j.seminhematol.2018.05.005_bib0044"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0046","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0047","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0048","series-title":"World Health Organization (WHO) classification of tumors. Pathology & genetics. Tumors of haematopoietic and lymphoid tissues","article-title":"Chronic eosinophilic leukaemia, NOS","author":"Bain","year":"2016"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0049","series-title":"World Health Organization (WHO) classification of tumors. Pathology & genetics. Tumors of haematopoietic and lymphoid tissues","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR 1, or with PCM1-JAK2","author":"Bain","year":"2016"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.iac.2007.06.001","article-title":"Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome","volume":"27","author":"Bain","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0051","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1038\/sj.onc.1206543","article-title":"Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571\/Glivec","volume":"22","author":"Trempat","year":"2003","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0052","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","article-title":"The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA","volume":"11","author":"Baxter","year":"2002","journal-title":"Human Mol Genet"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0053","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0054","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0055","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","article-title":"Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease","volume":"117","author":"Elling","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0056","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0057","first-page":"375","article-title":"Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears","volume":"86","author":"Bigoni","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0058","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.leu.2404397","article-title":"Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy","volume":"21","author":"Tokita","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0059","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ijlh.12057","article-title":"Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review","volume":"35","author":"Savage","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0061","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0062","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0063","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0064","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14728222.2011.538683","article-title":"PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms","volume":"15","author":"Hoeller","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0065","first-page":"195","article-title":"Eosinophilic leukemia: a myeloproliferative disorder distinct from the hypereosinophilic syndrome","volume":"5","author":"Kueck","year":"1991","journal-title":"Hematol Pathol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0066","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0067","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0068","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lefevre","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0069","first-page":"1086","article-title":"CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lefevre","year":"2015","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0070","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0071","first-page":"753","article-title":"6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome","volume":"90","author":"Ravoet","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0072","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0073","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0074","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0075","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0076","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome","volume":"330","author":"Cogan","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0077","first-page":"1086","article-title":"CD3\u2212CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lef\u00e8vre","year":"2015","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0079","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.05.005_bib0080","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/sj.leu.2404977","article-title":"The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus","volume":"21","author":"Burgstaller","year":"2007","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196318300362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196318300362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:26:04Z","timestamp":1758522364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196318300362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0037196318300362"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.05.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in diagnosis of mastocytosis and hypereosinophilic syndrome\u2606","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}